Product Description
The global transcatheter heart valve replacement market was valued at $7.7 billion in 2025. This is expected to increase over the forecast period at a CAGR of 6.7% to reach $12.1 billion.
The full report suite on the global market for transcatheter heart valve replacement (THVR) includes artificial valves placed in a minimally invasive catheter procedure to the aortic and pulmonary valves.
The report includes data for 65 countries across 7 different regions which include North America, Latin America, Western Europe, Central & Eastern Europe, Middle East, Asia-Pacific, and Africa.
Data Types Included
- Unit Sales, Average Selling Prices, Market Size & Growth Trends
- Procedure Numbers
- Market Drivers & Limiters
- Market Forecasts Until 2032, and Historical Data to 2022
- Recent Mergers & Acquisitions
- Company Profiles and Product Portfolios
- Leading Competitors
Transcatheter Heart Valve Replacement Market Trends
With multiple transcatheter aortic valve replacement (TAVR) devices now approved across major markets, the aortic valve replacement segment continues to expand and represents the largest share of the overall heart valve replacement market. Growing clinical evidence has demonstrated that TAVR offers comparable or superior safety outcomes relative to conventional surgical aortic valve replacement, particularly due to its less invasive nature, shorter recovery times, and reduced perioperative risk across a broad range of patient risk profiles. As indications expand and device technology continues to improve, TAVR adoption is expected to increase steadily over the forecast period.
Transcatheter Heart Valve Replacement Market Share Insights
- Edwards Lifesciences was the market leader in THVR devices in 2025. Edwards Lifesciences offers the SAPIEN 3®, SAPIEN XT® and CENTERA® transcatheter aortic valves. The SAPIEN 3® is used for aortic valve replacement, while the SAPIEN XT® is used for both aortic and pulmonary valve replacement. The company’s product lines in this segment are core devices across many regions, giving it space to maintain and grow overall market share.
- Medtronic made modest gains in the market for THVR devices in 2025 but remains behind Edwards Lifesciences globally. Medtronic offers the CoreValve™ Evolut™ Pro and CoreValve™ Evolut™ R System transcatheter aortic valves. Since Medtronic has left the ventricular assist device market, it is expected that it will expand its presence in the THVR segment.
- Abbott was the third-leading competitor in the THVR market in 2025. The company maintains a strong TAVR portfolio through its Portico™ and Navitor™ systems, supported by the FlexNav™ delivery platform, which enhances control and deliverability in complex anatomies. In 2025, Abbott received CE Mark approval in Europe for an expanded indication of the Navitor™ TAVR system to include low- and intermediate-risk patients, strengthening its global market position. Additionally, regulatory approvals for the TriClip™ G4 system in the U.S. (2024) and Japan (2025) further expanded Abbott’s presence across transcatheter valve therapies.
Transcatheter Heart Valve Replacement Market Segmentation Summary
- Transcatheter Heart Valve Replacement Market – Further Segmented Into:
- Device Type: Transcatheter Aortic Valve Replacement, Transcatheter Pulmonary Valve Replacement.
Research Scope Summary
| Report Attribute | Details |
|---|---|
| Regions | North America (Canada, United States) Latin America (Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, Guatemala, Mexico, Panama, Paraguay, Peru, Puerto Rico, Uruguay, Venezuela) Western Europe (Austria, Benelux, France, Germany, Italy, Portugal, Scandinavia, Spain, Switzerland, United Kingdom) Central & Eastern Europe (Azerbaijan, Baltic States, Belarus, Bulgaria, Croatia, Czech Republic, Georgia, Greece, Hungary, Kazakhstan, Poland, Romania, Russia, Serbia, Slovakia, Slovenia, Turkey, Ukraine) Middle East (Bahrain, Iran, Israel, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates) Asia Pacific (Australia, Cambodia, China, Hong Kong, India, Indonesia, Japan, Kyrgyzstan, Macao, Malaysia, Mongolia, Myanmar, New Zealand, Pakistan, Philippines, Singapore, South Korea, Sri Lanka, Taiwan, Thailand, Uzbekistan, Vietnam) Africa (Algeria, Egypt, Ethiopia, Ghana, Kenya, Libya, Morocco, Nigeria, South Africa, Sudan, Uganda) |
| Base Year | 2025 |
| Forecast | 2026-2032 |
| Historical Data | 2022-2024 |
| Quantitative Coverage | Procedure Numbers, Market Size, Market Shares, Market Forecasts, Market Growth Rates, Units Sold, and Average Selling Prices. |
| Qualitative Coverage | Market Growth Trends, Market Limiters, Competitive Analysis & SWOT for Top Competitors, Mergers & Acquisitions, Company Profiles, Product Portfolios, FDA Recalls, Disruptive Technologies, Disease Overviews. |
| Data Sources | Primary Interviews with Industry Leaders, Government Physician Data, Regulatory Data, Hospital Private Data, Import & Export Data, iData Research Internal Database. |
CONTACT US FOR ADDITIONAL INFORMATION
For full segmentation and any questions regarding research coverage, please contact us for a complimentary demo of the full report.
